COMMUNIQUÉS West-GlobeNewswire

Catheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure Assets
06/05/2025
FORT MILL, S.C., May 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac [...]
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
06/05/2025
Daxor’s Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement [...]
Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference
06/05/2025
Topline Results from the AP02 (Inhaled Nintedanib) Phase 1 Clinical Trials Among the Company’s Five Poster Presentations 4.5 Year Long-Term Safety and Efficacy Data Supporting AP01 (Inhaled Pirfenidone) from the ATLAS [...]
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
06/05/2025
VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of [...]
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
06/05/2025
Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumors SAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 [...]
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
06/05/2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
06/05/2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025
06/05/2025
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference [...]
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
06/05/2025
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept [...]
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
06/05/2025
MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare [...]
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
06/05/2025
ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
06/05/2025
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the [...]
Compass Therapeutics to Participate in Upcoming May Investor Events
06/05/2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that [...]
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
06/05/2025
NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at [...]
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
06/05/2025
Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 – covering burden, and the value of treatment and prevention Analysis of the [...]
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
06/05/2025
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study ( NCT06769048 ), investigating the efficacy and safety of BI 1584862 as a potential first-in-class [...]
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
06/05/2025
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a [...]
IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology
06/05/2025
Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage [...]
Candel Therapeutics to Present at Upcoming Investor Conferences
06/05/2025
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Pages